CPVL

Across TCGA pan-cancer cohorts, CPVL mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CPVL data layer compared with 29 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher CPVL mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CPVL expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

COAD, UCEC, and PDAC are the cancer types where CPVL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Quartile	All	0.829	1.000	.005	114	view →
UCEC	OS	Tertile	III,IV	0.305	1.000	.017	24	view →
PDAC	OS	Median	All	0.528	0.294	.017	10	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.775	.005	8	view →
HNSC	OS	Median	All	0.958	1.000	.020	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CPVL–COAD (DFS)

Open the COAD breakdown →